After 36 weeks of treatment, patients receiving sparsentan a

來源: 三絲 於 2023-01-03 20:24:19 [] [舊帖] [給我悄悄話] 閱讀數 : (777 bytes)
回答: TVTX 也沒有達到45% 由 小白石橋 於 2023-01-03 19:37:18

In August 2021, the Company announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan in IgAN. The PROTECT Study met its pre-specified interim primary efficacy endpoint with statistical significance. After 36 weeks of treatment, patients receiving sparsentan achieved a mean reduction in proteinuria from baseline of 49.8 percent, compared to a mean reduction in proteinuria from baseline of 15.1 percent for irbesartan-treated patients (p<0.0001). 

請您先登陸，再發跟帖！